Physician profile
Drew D Shoemaker
NPI 1851313399
$948.67
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $41.89 · 2021: $214 · 2022: $218 · 2023: $93.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $93.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $93.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $164.12 | 2021-2022 | |
| Indivior INC. | $136.01 | 2021-2023 | Sublocade |
| Pfizer INC. | $114.45 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $84.51 | 2022-2023 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Novo Nordisk INC | $76.88 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $52.70 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $47.05 | 2019 | |
| Glaxosmithkline, LLC. | $45.45 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $34.17 | 2019 | |
| Amgen INC. | $31.32 | 2019 | |
| Sunovion Pharmaceuticals INC. | $27.50 | 2019 | |
| Bioventus LLC | $23.08 | 2019 | |
| Daiichi Sankyo INC. | $18.20 | 2021 | |
| Sanofi Pasteur INC. | $17.74 | 2019 | |
| Amarin Pharma, INC. | $16.86 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $16.80 | 2022 | |
| Lilly USA, LLC | $15.37 | 2020 | |
| Allergan, INC. | $13.61 | 2020 | |
| Alkermes, INC. | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Shoemaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.